Last reviewed · How we verify
NCT03200210: LUMINA
Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients
Phase 4 trial testing Febuxostat in Hyperuricemia in 548 participants. Status unknown.
31 December 2022
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 548 |
| Start date | 11 July 2017 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Febuxostat (FEBUXOSTAT) — full drug profile →
- Placebo
Conditions studied
- Hyperuricemia — all drugs for Hyperuricemia →
Sponsor
Sun Yat-sen University
Who can join
Adults 18 to 70, any sex, with Hyperuricemia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will enroll continuous ambulatory peritoneal dialysis (CAPD) patients with hyperuricemia and randomly divide them into two groups, treated with Febuxostat and placebo respectively. After 3 years of following up, cardiovascular events, all cause mortality, cardiovascular mortality and non-fatal cardiovascular events are collected and recorded. The difference of cardiovascular events, all cause mortality and non-fatal cardiovascular event rate will be analyzed.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update.
Cicero AFG, Fogacci F, Kuwabara M, Borghi C. · · 2021 · cited 50× · PMID 33435164 · DOI 10.3390/medicina57010058 -
Effects of Febuxostat on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Al-Abdouh A, Khan SU, Barbarawi M, Upadhrasta S, et al · · 2020 · cited 9× · PMID 32793871 · DOI 10.1016/j.mayocpiqo.2020.04.012 -
Rationale and design for Lowering-hyperUricaemia treatment on cardiovascular outcoMes In peritoNeal diAlysis patients: a prospective, multicentre, double-blind, randomised controlled trial (LUMINA).
Chen W, Huang N, Mao H, Yang X, et al · · 2020 · cited 1× · PMID 33040002 · DOI 10.1136/bmjopen-2020-037842
Verify or expand the search:
- PubMed search for NCT03200210
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Febuxostat
Trials testing the same drug.
- NCT07498647 — Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia · Phase 2 · not yet recruiting
- NCT07414394 — Tigulixostat (IBI128) vs Febuxostat in Gout · Phase 3 · recruiting
- NCT07369622 — HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness · Phase 4 · not yet recruiting
- NCT07170475 — A Phase Ib Trial of Combined Febuxostat and Inosine Therapy in Patients With Parkinson's Disease · Phase 1 · recruiting
- NCT06834230 — Effect of Dotinurad in Hyperuricemia With Hypertension · Phase 4 · recruiting
Other recruiting trials for Hyperuricemia
Currently open trials in the same condition.
- NCT07144332 — This Study is to Estimate the Efficacy of Hemodialysis Alone for Uric Acid Clearance in Patients on Hemodialysis. In Ord · recruiting
- NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
- NCT06859073 — A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia · Phase 1 · recruiting
- NCT06463561 — CPAP Effect on Lipid Profile and Hyperuricemia in Patients With Dyslipidemia and Moderate-severe Obstructive Sleep Apnea · Phase 4 · recruiting
- NCT06729853 — PK and Safety Evaluation Study of SAP-001 in Adult Subjects With Normal and Impaired Renal Function · Phase 1, PHASE2 · active not recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03200210 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 22 October 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03200210.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing